Pilot Study to Assess the Efficacy of Botulinum Toxin B on Pain and Disability in Subjects With Acute Low Back Pain
Status:
Terminated
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
This study will test the hypothesis that Botulinum toxin B (Myobloc®) treatment reduces pain
and disability in subjects suffering from acute low back pain due to an identifiable muscle
strain or back trauma occurring 3 to 6 weeks prior to enrollment. The study will also
delineate the duration of medication effect and control for any placebo or mechanical
trigger-point injection effect by employing a prospective, double-blind, placebo-controlled
design.